Latest news with #trachoma
Zawya
15-07-2025
- Health
- Zawya
Senegal joins growing list of countries that have eliminated trachoma
The World Health Organization (WHO) has validated Senegal as having eliminated trachoma as a public health problem. Senegal becomes the ninth country in WHO's African Region to have achieved this feat. 'I commend Senegal for freeing its population from this disease', said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. 'This milestone is yet another sign of the remarkable progress being made against neglected tropical diseases globally, and offers hope to other countries still working to eliminate trachoma.' Trachoma has been known in Senegal since the early 1900s and was confirmed as a major cause of blindness through surveys in the 1980s and 1990s. Senegal joined the WHO Alliance for the Global Elimination of Trachoma in 1998, conducted its first national survey in 2000, and completed full disease mapping by 2017 with support from the Global Trachoma Mapping Project and Tropical Data. Trachoma control was consistently integrated into national eye health programmed, first under the National Program for Blindness Prevention (PNLC) and later through the National Program for the Promotion of Eye Health (PNPSO) – maintaining its commitment to trachoma elimination. 'Today we celebrate our victory against trachoma, 21 years after the one against dracunculiasis' said Dr Ibrahima Sy, Senegal's Minister of Health and Social Action. 'This new milestone reminds us that our overarching goal remains a Senegal free from neglected tropical diseases. We are fully committed to this, and we are making good progress, notably against human African trypanosomiasis (sleeping sickness) and onchocerciasis'. Senegal implemented the WHO-recommended SAFE strategy to eliminate trachoma with the support of partners, reaching 2.8 million people who needed them across 24 districts. These activities included provision of surgery to treat the late blinding stage of the disease, conducting antibiotic mass drug administration of azithromycin donated by Pfizer through the International Trachoma Initiative, carrying out public awareness campaigns to promote facial cleanliness, and improvement in access to water supply and sanitation. Trachoma is the second neglected tropical disease to be eliminated in Senegal. In 2004, the country was certified free of dracunculiasis (Guinea-worm disease) transmission. Globally, Senegal joins 24 other countries that have been validated by WHO for having eliminated trachoma as a public health problem. These are Benin, Burundi, Cambodia, China, Gambia, Islamic Republic of Iran, Lao People's Democratic Republic, Ghana, India, Iraq, Malawi, Mali, Mauritania, Mexico, Morocco, Myanmar, Nepal, Oman, Pakistan, Papua New Guinea, Saudi Arabia, Togo, Vanuatu and Viet Nam. These countries are part of a wider of group of 57 countries that have eliminated one or more neglected tropical diseases. WHO is supporting Senegal's health authorities to closely monitor communities in which trachoma was previously endemic to ensure there is no resurgence of the disease. 'Trachoma has cast a shadow over communities in Senegal for more than a century. This long-awaited validation is not only a milestone for public health but a powerful tribute to the tireless dedication of frontline health workers, communities, government leaders, and partners who never gave up,' said Dr Jean-Marie Vianny Yameogo, WHO Representative in Senegal. 'Today, we close a chapter that began over a hundred years ago, united with pride, gratitude and resolve. WHO remains committed to supporting Senegal as the country continues to lead in sustaining this hard-earned achievement.' Disease prevalence Trachoma remains a public health problem in 32 countries, with an estimated 103 million people living in areas requiring interventions against the disease. Trachoma is found mainly in the poorest and most rural areas of Africa, Central and South America, Asia, the Western Pacific and the Middle East. WHO's African Region is disproportionately affected by trachoma, with 93 million people living in at-risk areas in April 2024, representing 90% of the global trachoma burden. Significant progress has been made in the fight against trachoma over the past few years and the number of people requiring antibiotic treatment for trachoma in the African Region fell by 96 million from 189 million in 2014 to 93 million as of April 2024, representing a 51% reduction. There are currently 20 countries (Algeria, Angola, Burkina Faso, Cameroon, Central Africa Republic, Chad, Côte d'Ivoire, Democratic Republic of the Congo, Eritrea, Ethiopia, Guinea, Kenya, Mozambique, Niger, Nigeria, South Sudan, United Republic of Tanzania, Uganda, Zambia and Zimbabwe) in WHO's African Region that are known to require intervention for trachoma elimination. A further 3 countries in the Region (Botswana, Guinea-Bissau and Namibia) claim to have achieved the prevalence targets for elimination.
Zawya
11-07-2025
- Health
- Zawya
Burundi eliminates trachoma as a public health problem
The World Health Organization (WHO) has validated Burundi as having eliminated trachoma as a public health problem, making it the eighth country in WHO's African Region to reach this important milestone. Trachoma is also the first neglected tropical disease (NTD) to be eliminated in the country. 'Eliminating a disease like trachoma is a major public health achievement that requires sustained effort and dedication,' said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. 'I congratulate the government and the people of Burundi and commend them for their hard work and commitment. It is great to see Burundi join the growing group of countries that have eliminated at least one NTD'. Trachoma is caused by the bacterium Chlamydia trachomatis and spreads through personal contact, contaminated surfaces and by flies that have been in contact with eye or nose discharge. Repeated infections can lead to scarring, in-turning of the eyelids, and ultimately blindness. Globally, the disease remains endemic in many vulnerable communities where access to clean water and sanitation is limited. 'This validation marks a major milestone in our commitment to health equity', said Dr Lydwine Baradahana, Minister of Public Health and the Fight Against AIDS, Burundi. 'It is a collective victory made possible by nearly 20 years of national mobilization and international solidarity. I thank all the partners, community actors and institutions in Burundi and beyond who made this historic achievement possible'. Burundi's progress Before 2007, with no reported cases or epidemiological studies, the extent of trachoma endemicity in Burundi was largely unknown. That year, the country launched an initiative to tackle NTDs, which included integrated mapping of soil-transmitted helminthiases, schistosomiasis, lymphatic filariasis and trachoma. Following the mapping, the Ministry of Public Health and the Fight Against AIDS conducted further investigations. Baseline surveys carried out in 2009–2010 confirmed that trachoma was endemic in parts of the country. This prompted introduction of interventions based on the WHO-recommended SAFE strategy for 2.5 million people who needed them across 12 health districts. Burundi's trachoma elimination programme was supported technically and financially by CBM Christoffel Blindenmission, the END Fund, Geneva Global and WHO. The International Trachoma Initiative at the Task Force for Global Health donated azithromycin (Zithromax, Pfizer, New York NY, USA). WHO continues to support support the country's health authorities to monitor communities in which trachoma was previously endemic to ensure there is no resurgence of the disease. This achievement reflects the government's resolve to protect its most vulnerable populations. Under the leadership of the Ministry of Public Health and the Fight Against AIDS, and with the dedication of community health workers, support from key partners, and WHO's technical guidance, this success was made possible' said Dr Xavier Crespin, WHO Representative in Burundi. 'This win inspires us to press forward with the same determination to eliminate all remaining neglected tropical diseases.' Disease prevalence Trachoma remains a public health problem in 32 countries with an estimated 103 million people living in areas requiring interventions against the disease. Trachoma is found mainly in the poorest and most rural areas of Africa, Central and South America, Asia, the Western Pacific and the Middle East. The African Region is disproportionately affected by trachoma with 93 million people living in at-risk areas in April 2024, representing 90% of the global trachoma burden. Significant progress has been made in the fight against trachoma over the past few years and the number of people requiring antibiotic treatment for trachoma in the African Region fell by 96 million from 189 million in 2014 to 93 million as of April 2024, representing a 51% reduction. There are currently 20 countries in WHO's African Region that are known to require intervention for trachoma elimination. These include: Algeria, Angola, Burkina Faso, Cameroon, Central Africa Republic, Chad, Côte d'Ivoire, Democratic Republic of the Congo, Eritrea, Ethiopia, Guinea, Kenya, Mozambique, Niger, Nigeria, South Sudan, United Republic of Tanzania, Uganda, Zambia and Zimbabwe. The seven countries in the region previously validated by WHO as having eliminated trachoma as a public health problem are Benin, Gambia, Ghana, Malawi, Mali, Mauritania and Togo. A further 4 countries in the WHO African Region (Botswana, Guinea-Bissau, Namibia and Senegal) claim to have achieved the prevalence targets for elimination. Global progress With today's announcement, a total of 57 countries have now eliminated at least one NTD. Of these, 24— (including Burundi)—have successfully eliminated trachoma as a public health problem. Other countries that have reached this milestone include Benin, Cambodia, China, Gambia, Islamic Republic of Iran, Lao People's Democratic Republic, Ghana, India, Iraq, Malawi, Mali, Mauritania, Mexico, Morocco, Myanmar, Nepal, Oman, Pakistan, Papua New Guinea, Saudi Arabia, Togo, Vanuatu and Viet Nam. Distributed by APO Group on behalf of World Health Organization (WHO).
